3D MEDICINES (01244.HK): 3D189 Hits REGAL Endpoint, Death Risk -41%
NewTimeSpace News: On 18 November 2026, 3D Medicines Inc. (stock code: 1244) announced on a voluntary basis that its collaboration partner SELLAS Life Sciences Group, Inc. reported on 17 November 2026 the positive topline primary endpoint results of the global pivotal randomised Phase 3 REGAL trial (Trial ID: NCT04229979).
According to the announcement, the trial evaluates 3D189 (Galinpepimut-S, GPS), a WT1-targeted therapeutic cancer vaccine in the Group's collaborative pipeline, as single-agent maintenance therapy for acute myeloid leukaemia patients who have achieved second or later complete remission and are ineligible for allogeneic stem cell transplantation. The REGAL trial successfully met its pre-specified primary efficacy endpoint: compared with the investigator's choice of best available treatment, 3D189 reduced the risk of death by 41%, with a hazard ratio of 0.59 and a two-sided p-value of 0.035, demonstrating statistically significant and clinically meaningful benefits; median overall survival reached 24.0 months in the 3D189 arm versus 14.7 months in the control arm.
On safety, 3D189 was generally well tolerated, with a profile consistent with previous clinical studies, no new safety signals and treatment-related adverse events mostly mild to moderate local injection reactions. SELLAS intends to communicate with the U.S. Food and Drug Administration to explore an accelerated approval pathway and plans to submit a Biologics License Application in the first half of 2027; full secondary endpoint data, subgroup analyses and supplementary results will be presented at international medical conferences and published in academic journals. The Company cautioned that clinical study results are uncertain and will disclose further progress in a timely manner.
- 3D MEDICINES (01244.HK): Envafolimab Moves to Regular Approval
- 3D MEDICINES (01244.HK): 3D189/GPS Phase 3 REGAL Hits Pre-specified 80 Events
- 3D MEDICINES (01244.HK): arbitration award against SELLAS Life Sciences fully received and executed, approximately HKD 7.98 million
- Autonomous Driving Concept Stocks Insight | XPENG-W (09868.HK) Posts Q3 Revenue and Delivery Growth, Secures Guangzhou Citywide L4 Robotaxi Demonstration Operation Qualification
- Autonomous Driving Concept Stocks Insight | XPENG-W (09868.HK) Edged Lower, XPeng GX, G9L and Other Models Launched for Sales in 11 Middle Eastern and African Countries